

References for the Clinical Content of the BPSD section of the site

1. Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. *The British journal of psychiatry : the journal of mental science*. 2009;194.
2. Ornstein K, Gaugler JE. The problem with "problem behaviors": a systematic review of the association between individual patient behavioral and psychological symptoms and caregiver depression and burden within the dementia patient-caregiver dyad. *International psychogeriatrics / IPA*. 2012;24(10):1536-52.
3. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. *Neuropsychopharmacology*. 2008;33(5):957-70.
4. Brodaty H, Connors MH, Xu J, Woodward M, Ames D. Predictors of institutionalization in dementia: a three year longitudinal study. *Journal of Alzheimer's disease : JAD*. 2014;40(1):221-6.
5. Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. *J Am Geriatr Soc*. 2014;62(4):762-9.
6. Lawlor BA. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. *The Journal of clinical psychiatry*. 2004;65 Suppl 11:5-10.
7. Buhagiar K, Afzal N, Cosgrave M. Behavioural and psychological symptoms of dementia in primary care: a survey of general practitioners in Ireland. *Mental health in family medicine*. 2011;8(4):227-34.
8. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. *Cochrane Database Syst Rev*. 2006(1):Cd003476.
9. Pratt N, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. *Drug safety*. 2011;34(7):567-75.
10. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2006;14(3):191-210.
11. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. *JAMA psychiatry*. 2015;72(5):438-45.
12. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. *Expert opinion on drug safety*. 2011;10(1):35-43.
13. Ballard C, Corbett A, Howard R. Prescription of antipsychotics in people with dementia. *The British journal of psychiatry : the journal of mental science*. 2014;205(1):4-5.
14. Azermai M. Dealing with behavioral and psychological symptoms of dementia: a general overview. *Psychology research and behavior management*. 2015;8:181-5.
15. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. *The American journal of psychiatry*. 2012;169(9):946-53.
16. Testad I, Corbett A, Aarsland D, Lexow KO, Fossey J, Woods B, et al. The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. *International psychogeriatrics / IPA*. 2014;26(7):1083-98.
17. Ueda T, Suzukamo Y, Sato M, Izumi S. Effects of music therapy on behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. *Ageing research reviews*. 2013;12(2):628-41.
18. de Oliveira AM, Radanovic M, de Mello PC, Buchain PC, Vizzotto AD, Celestino DL, et al. Nonpharmacological Interventions to Reduce Behavioral and Psychological Symptoms of Dementia: A Systematic Review. *BioMed research international*. 2015;2015:218980.

19. Marston L, Nazareth I, Petersen I, Walters K, Osborn DP. Prescribing of antipsychotics in UK primary care: a cohort study. *BMJ Open*. 2014;4(12):e006135.
20. Foley T. SG. *Dementia: Diagnosis and Management in General Practice*2014:[22 p.].
21. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. *Eur J Neurol*. 2010;17(10):1236-48.
22. Fick DM, Hodo DM, Lawrence F, Inouye SK. Recognizing delirium superimposed on dementia: assessing nurses' knowledge using case vignettes. *Journal of gerontological nursing*. 2007;33(2):40-7; quiz 8-9.
23. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. *Annals of internal medicine*. 1990;113(12):941-8.
24. Lawley D. Pathway for the Assessment and Management of Behavioural and Psychological Symptoms of Dementia (BPSD)2012. Available from: <http://www.hey.nhs.uk/herpc/guidelines/BPSDGuideline.pdf>.
25. Algorithm for Accommodating and Managing Behavioural and Psychological Symptoms of Dementia in Residential Care2012. Available from: <http://bcbpsd.ca/about.php>.
26. Kim Burns RJ, Ruby Tsang, Henry Brodaty. Behaviour Management - A Guide to Good Practice2012. Available from: http://www.dementiaresearch.org.au/images/dcrc/output-files/328-2012_dbmas_bpsd_guidelines_guide.pdf.
27. Kozman MN, Wattis J, Curran S. Pharmacological management of behavioural and psychological disturbance in dementia. *Human psychopharmacology*. 2006;21(1):1-12.
28. Optimising treatment and care for behavioural and psychological symptoms of dementia A best practice guide. . Alzheimer's society, Dementia Action Alliance, Royal College of General Practitioners, Department of Health; 2011.
29. Zieber CG, Hagen B, Armstrong-Esther C, Aho M. Pain and agitation in long-term care residents with dementia: use of the Pittsburgh Agitation Scale. *International journal of palliative nursing*. 2005;11(2):71-8.
30. Lane P. Assessing pain in patients with advanced dementia. *Nursing*. 2004;34(8):17.
31. Feldt KS, Warne MA, Ryden MB. Examining pain in aggressive cognitively impaired older adults. *Journal of gerontological nursing*. 1998;24(11):14-22.
32. McClean WJ, Higginbotham NH. Prevalence of pain among nursing home residents in rural New South Wales. *The Medical journal of Australia*. 2002;177(1):17-20.
33. Fox PL, Raina P, Jadad AR. Prevalence and treatment of pain in older adults in nursing homes and other long-term care institutions: a systematic review. *Cmaj*. 1999;160(3):329-33.
34. Malara A, Andrea De Biase G, Bettarini F, Ceravolo F, Di Cello S, Garo M, et al. Pain Assessment in Elderly with Behavioral and Psychological Symptoms of Dementia. *Journal of Alzheimer's disease : JAD*. 2016.
35. Abbey J, Piller N, De Bellis A, Esterman A, Parker D, Giles L, et al. The Abbey pain scale: a 1-minute numerical indicator for people with end-stage dementia. *International journal of palliative nursing*. 2004;10(1):6-13.
36. Chibnall JT, Tait RC, Harman B, Luebbert RA. Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia. *J Am Geriatr Soc*. 2005;53(11):1921-9.
37. Husebo BS, Ballard C, Aarsland D. Pain treatment of agitation in patients with dementia: a systematic review. *International journal of geriatric psychiatry*. 2011;26(10):1012-8.
38. Thorpe L. Depression vs. Dementia: How Do We Assess? *The Canadian Review of Alzheimer's Disease and Other Dementias*. 2009(September):17 - 21.
39. Hersch EC, Falzgraf S. Management of the behavioral and psychological symptoms of dementia. *Clin Interv Aging*. 2007;2(4):611-21.
40. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. *J Am Geriatr Soc*. 2002;50(5):836-42.

41. Garland K, Beer E, Eppingstall B, O'Connor DW. A comparison of two treatments of agitated behavior in nursing home residents with dementia: simulated family presence and preferred music. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2007;15(6):514-21.
42. Sung HC, Lee WL, Li TL, Watson R. A group music intervention using percussion instruments with familiar music to reduce anxiety and agitation of institutionalized older adults with dementia. *International journal of geriatric psychiatry*. 2012;27(6):621-7.
43. Svansdottir HB, Snaedal J. Music therapy in moderate and severe dementia of Alzheimer's type: a case-control study. *International psychogeriatrics / IPA*. 2006;18(4):613-21.
44. Holmes C, Knights A, Dean C, Hodkinson S, Hopkins V. Keep music live: music and the alleviation of apathy in dementia subjects. *International psychogeriatrics / IPA*. 2006;18(4):623-30.
45. Yang MH, Lin LC, Wu SC, Chiu JH, Wang PN, Lin JG. Comparison of the efficacy of aroma-acupressure and aromatherapy for the treatment of dementia-associated agitation. *BMC complementary and alternative medicine*. 2015;15:93.
46. Lin PW, Chan WC, Ng BF, Lam LC. Efficacy of aromatherapy (*Lavandula angustifolia*) as an intervention for agitated behaviours in Chinese older persons with dementia: a cross-over randomized trial. *International journal of geriatric psychiatry*. 2007;22(5):405-10.
47. Neal M, Barton Wright P. Validation therapy for dementia. *Cochrane Database Syst Rev*. 2003(3):Cd001394.
48. Best Practice Guideline for Accommodating and Managing Behavioural and Psychological Symptoms of Dementia in Residential Care. *British Columbia Guidelines and Protocols Advisory Committee*.; 2012.
49. Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). *PLoS Med*. 2008;5(4):e76.
50. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. *Nature reviews Neuroscience*. 2006;7(6):492-500.
51. Onor ML, Saina M, Aguglia E. Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia. *American journal of Alzheimer's disease and other dementias*. 2006;21(6):448-53.
52. Maher AR, Maglione M, Bagley S, Suttrop M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. *Jama*. 2011;306(12):1359-69.
53. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *N Engl J Med*. 2006;355(15):1525-38.
54. Cummings J, Lai TJ, Hemrungronj S, Mohandas E, Yun Kim S, Nair G, et al. Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies. *CNS neuroscience & therapeutics*. 2016.
55. Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, et al. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. *The British journal of psychiatry : the journal of mental science*. 2014;205(1):44-51.
56. Neef D, Walling AD. Dementia with Lewy bodies: an emerging disease. *American family physician*. 2006;73(7):1223-9.
57. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. *Jama*. 2005;293(5):596-608.
58. Grimmer T, Kurz A. Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review. *Drugs & aging*. 2006;23(12):957-67.
59. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. *Jama*. 2003;289(2):210-6.

60. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al. Donepezil for the treatment of agitation in Alzheimer's disease. *N Engl J Med.* 2007;357(14):1382-92.
61. Pinto T, Lanctot KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. *Ageing research reviews.* 2011;10(4):404-12.
62. Ballard C, Thomas A, Gerry S, Yu LM, Aarsland D, Merritt C, et al. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). *J Am Med Dir Assoc.* 2015;16(4):316-22.
63. Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. *PloS one.* 2012;7(5):e35185.
64. Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. *Neurology.* 2005;65(3):481-2.
65. Menendez-Gonzalez M, Calatayud MT, Blazquez-Menes B. Exacerbation of Lewy bodies dementia due to memantine. *Journal of Alzheimer's disease : JAD.* 2005;8(3):289-91.
66. Camargos EF, Louzada LL, Quintas JL, Naves JO, Louzada FM, Nobrega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.* 2014;22(12):1565-74.
67. Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. *Cochrane Database Syst Rev.* 2004(4):Cd004990.
68. Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. *Cochrane Database Syst Rev.* 2009(3):Cd003945.
69. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc.* 2015;63(11):2227-46.
70. Tampi RR, Tampi DJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. *American journal of Alzheimer's disease and other dementias.* 2014;29(7):565-74.
71. Voyer P, Verreault R, Azizah GM, Desrosiers J, Champoux N, Bedard A. Prevalence of physical and verbal aggressive behaviours and associated factors among older adults in long-term care facilities. *BMC Geriatr.* 2005;5:13.
72. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. *Postgraduate medicine.* 2005;Spec No:6-22.
73. Cumbo E, Ligor LD. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial. *Journal of Alzheimer's disease : JAD.* 2014;39(3):477-85.
74. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. *Neurology.* 2004;63(2):214-9.
75. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. *The Journal of clinical psychiatry.* 2008;69(3):341-8.
76. Kong EH. Agitation in dementia: concept clarification. *J Adv Nurs.* 2005;52(5):526-36.
77. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. *Nature reviews Neurology.* 2009;5(5):245-55.
78. Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Cummings J, Grossberg GT, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement

- on treatment options, clinical trials methodology, and policy. *The Journal of clinical psychiatry*. 2008;69(6):889-98.
79. Verhey FR, Verkaaik M, Lousberg R. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. *Dementia and geriatric cognitive disorders*. 2006;21(1):1-8.
 80. Onor ML, Saina M, Trevisiol M, Cristante T, Aguglia E. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia. *Progress in neuro-psychopharmacology & biological psychiatry*. 2007;31(1):205-9.
 81. Holmes C, Wilkinson D, Dean C, Clare C, El-Okl M, Hensford C, et al. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. *International journal of geriatric psychiatry*. 2007;22(4):380-1.
 82. Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. *Neurology*. 2007;68(17):1356-63.
 83. Mahlberg R, Walther S, Eichmann U, Tracik F, Kunz D. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study. *Archives of gerontology and geriatrics*. 2007;45(1):19-26.
 84. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. *Cochrane Database Syst Rev*. 2011(2):Cd008191.
 85. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. *Jama*. 2014;311(7):682-91.
 86. Sepehry AA, Lee PE, Hsiung GY, Beattie BL, Jacova C. Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. *Drugs & aging*. 2012;29(10):793-806.
 87. Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, et al. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2015;23(11):1127-33.
 88. Cakir S, Kulaksizoglu IB. The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study. *Neuropsychiatric disease and treatment*. 2008;4(5):963-6.
 89. Twelftree H, Qazi A. Relationship between anxiety and agitation in dementia. *Aging & mental health*. 2006;10(4):362-7.
 90. Starkstein SE, Jorge R, Petracca G, Robinson RG. The construct of generalized anxiety disorder in Alzheimer disease. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2007;15(1):42-9.
 91. Beaudreau SA, O'Hara R. Late-life anxiety and cognitive impairment: a review. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2008;16(10):790-803.
 92. Zec RF, Burkett NR. Non-pharmacological and pharmacological treatment of the cognitive and behavioral symptoms of Alzheimer disease. *NeuroRehabilitation*. 2008;23(5):425-38.
 93. Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, et al. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. *The British journal of psychiatry : the journal of mental science*. 2013;202:121-8.
 94. Raji MA, Brady SR. Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. *The Annals of pharmacotherapy*. 2001;35(9):1024-7.
 95. Lopez-Pousa S, Garre-Olmo J, Vilalta-Franch J, Turon-Estrada A, Pericot-Nierga I. Trazodone for Alzheimer's disease: a naturalistic follow-up study. *Archives of gerontology and geriatrics*. 2008;47(2):207-15.
 96. Wilkins JM, Forester BP. Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia. *Current psychiatry reports*. 2016;18(2):14.

97. Bains J, Birks J, Denning T. Antidepressants for treating depression in dementia. *Cochrane Database Syst Rev.* 2002(4):Cd003944.
98. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. *Archives of general psychiatry.* 2003;60(7):737-46.
99. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. *Lancet.* 2011;378(9789):403-11.
100. Barkin RL. Sertraline and mirtazapine do not reduce severity of depression in people with dementia. *Evidence-based mental health.* 2012;15(1):17.
101. Kitching D. Depression in dementia. *Australian prescriber.* 2015;38(6):209-2011.
102. Siarkos KT, Katirtzoglou EA, Politis AM. A Review of Pharmacological Treatments for Depression in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD.* 2015;48(1):15-34.
103. McCurry SM, Gibbons LE, Logsdon RG, Vitiello MV, Teri L. Nighttime insomnia treatment and education for Alzheimer's disease: a randomized, controlled trial. *J Am Geriatr Soc.* 2005;53(5):793-802.
104. McCurry SM, Pike KC, Vitiello MV, Logsdon RG, Larson EB, Teri L. Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer's disease: results of a randomized, controlled trial. *J Am Geriatr Soc.* 2011;59(8):1393-402.
105. McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer's disease. *Cochrane Database Syst Rev.* 2014;3:Cd009178.
106. Gauthier S, Juby A, Dalziel W, Rehel B, Schechter R. Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE). *Current medical research and opinion.* 2010;26(5):1149-60.
107. Naharci MI, Ozturk A, Yasar H, Cintosun U, Kocak N, Bozoglu E, et al. Galantamine improves sleep quality in patients with dementia. *Acta neurologica Belgica.* 2015;115(4):563-8.
108. Moraes Wdos S, Poyares DR, Guilleminault C, Ramos LR, Bertolucci PH, Tufik S. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. *Sleep.* 2006;29(2):199-205.
109. Hermans DG, Htay UH, McShane R. Non-pharmacological interventions for wandering of people with dementia in the domestic setting. *Cochrane Database Syst Rev.* 2007(1):Cd005994.
110. Price JD, Hermans DG, Grimley Evans J. Subjective barriers to prevent wandering of cognitively impaired people. *Cochrane Database Syst Rev.* 2000(4):Cd001932.
111. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. *BMJ (Clinical research ed).* 2015;350:h369.
112. Lawlor B. *A Pocket Positive Guide to Dementia: Trinity Brain Health, Trinity College Dublin, Dublin 2, Ireland; 2015.*
113. Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. *Cochrane Database Syst Rev.* 2013;3:Cd007726.
114. Pan YJ, Wu CS, Gau SS, Chan HY, Banerjee S. Antipsychotic discontinuation in patients with dementia: a systematic review and meta-analysis of published randomized controlled studies. *Dementia and geriatric cognitive disorders.* 2014;37(3-4):125-40.
115. NHS. Reducing Antipsychotic Prescribing in Dementia Toolkit 2014. Available from: <http://www.prescripp.info/resources/viewcategory/241-reducing-antipsychotic-prescribing-in-dementia-toolkit>.

References for the Clinical Content of the Diagnosis Pathway of the site

- 1 Suzanne Cahill, E. O. S. M. P. Creating Excellence in Dementia Care; A research review for Ireland's National Dementia Strategy. (Department of Health, 2012).
- 2 Trepel, D. An update on the economics of dementia care in Ireland. *Irish medical journal* **105**, 38-39 (2012).
- 3 Cahill, S. *et al.* The attitudes and practices of general practitioners regarding dementia diagnosis in Ireland. *International journal of geriatric psychiatry* **23**, 663-669, doi:10.1002/gps.1956 (2008).
- 4 Manthorpe, J. *et al.* From forgetfulness to dementia: clinical and commissioning implications of diagnostic experiences. *The British journal of general practice : the journal of the Royal College of General Practitioners* **63**, e69-75, doi:10.3399/bjgp13X660805 (2013).
- 5 Irish National Dementia Strategy (Dept. of Health, 2015).
- 6 Buntinx, F., De Lepeleire, J., Paquay, L., Iliffe, S. & Schoenmakers, B. Diagnosing dementia: no easy job. *BMC family practice* **12**, 60, doi:10.1186/1471-2296-12-60 (2011).
- 7 Kitzinger, J. Qualitative research. Introducing focus groups. *Bmj* **311**, 299-302 (1995).
- 8 Greenhalgh, T. & Taylor, R. Papers that go beyond numbers (qualitative research). *Bmj* **315**, 740-743 (1997).
- 9 Patton, M. *Qualitative evaluation and research methods*. Vol. 2nd ed (Sage, 1990).
- 10 Mays, N. Qualitative research in health care: Assessing quality in qualitative research. *Bmj* **320**, 50-52, doi:10.1136/bmj.320.7226.50 (2000).
- 11 Shulman, K. I. *et al.* IPA survey of brief cognitive screening instruments. *International psychogeriatrics / IPA* **18**, 281-294, doi:10.1017/S1041610205002693 (2006).
- 12 Milne, A., Culverwell, A., Guss, R., Tuppen, J. & Whelton, R. Screening for dementia in primary care: a review of the use, efficacy and quality of measures. *International psychogeriatrics / IPA* **20**, 911-926, doi:10.1017/S1041610208007394 (2008).
- 13 Lorentz, W. J., Scanlan, J. M. & Borson, S. Brief screening tests for dementia. *Canadian journal of psychiatry. Revue canadienne de psychiatrie* **47**, 723-733 (2002).
- 14 Brodaty, H., Low, L. F., Gibson, L. & Burns, K. What is the best dementia screening instrument for general practitioners to use? *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry* **14**, 391-400, doi:10.1097/01.JGP.0000216181.20416.b2 (2006).
- 15 van Hout, H., Vernooij-Dassen, M., Poels, P., Hoefnagels, W. & Grol, R. Are general practitioners able to accurately diagnose dementia and identify Alzheimer's disease? A comparison with an outpatient memory clinic. *The British journal of general practice : the journal of the Royal College of General Practitioners* **50**, 311-312 (2000).
- 16 NICE. Supporting people with dementia and their carers in health and social care (updated 2015).
- 17 (SIGN), S. I. G. N. Management of patients with dementia (2006).

- 18 Pinner, G. & Bouman, W. P. Attitudes of patients with mild dementia and their carers towards disclosure of the diagnosis. *International psychogeriatrics / IPA* **15**, 279-288 (2003).
- 19 Bamford, C. *et al.* Disclosing a diagnosis of dementia: a systematic review. *International journal of geriatric psychiatry* **19**, 151-169, doi:10.1002/gps.1050 (2004).
- 20 Carpenter, B. & Dave, J. Disclosing a dementia diagnosis: a review of opinion and practice, and a proposed research agenda. *The Gerontologist* **44**, 149-158 (2004).
- 21 Lecouturier, J. *et al.* Appropriate disclosure of a diagnosis of dementia: identifying the key behaviours of 'best practice'. *BMC health services research* **8**, 95, doi:10.1186/1472-6963-8-95 (2008).
- 22 Woods, R. T. *et al.* Dementia: issues in early recognition and intervention in primary care. *Journal of the Royal Society of Medicine* **96**, 320-324 (2003).
- 23 Downs, M. *et al.* Effectiveness of educational interventions in improving detection and management of dementia in primary care: cluster randomised controlled study. *Bmj* **332**, 692-696, doi:10.1136/bmj.332.7543.692 (2006).
- 24 Perry, M. *et al.* Effects of educational interventions on primary dementia care: A systematic review. *International journal of geriatric psychiatry* **26**, 1-11, doi:10.1002/gps.2479 (2011).
- 25 Rabins *et al.* Practical Dementia Care. Table 2.1 (p17) (2004)

Main Sources of Information for our Driving with Dementia Section
--

1. Carter K, Monaghan S, O'Brien J, Teodorczuk A, Mosimann U, Taylor JP. Driving and dementia: a clinical decision pathway. *International journal of geriatric psychiatry*. 2015;30(2):210-6.
2. Slainte agus Tiomaint: Medical Fitness to Drive Guidelines. April 2016